RESTON, Va., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Science Applications International Corp. (NASDAQ: SAIC ) announced today that the company's board of directors declared a cash dividend of $0.37 per share of the company's common stock payable on January 24, 2025 to stockholders of record on January 10, 2025. SAIC intends to continue paying dividends on a quarterly basis, although the declaration of any future dividends will be determined by the board of directors each quarter and will depend on earnings, financial condition, capital requirements and other factors. About SAIC SAIC is a premier Fortune 500® technology integrator focused on advancing the power of technology and innovation to serve and protect our world. Our robust portfolio of offerings across the defense, space, civilian and intelligence markets includes secure high-end solutions in mission IT, enterprise IT, engineering services and professional services. We integrate emerging technology, rapidly and securely, into mission critical operations that modernize and enable critical national imperatives. We are approximately 24,000 strong; driven by mission, united by purpose, and inspired by opportunities. SAIC is an Equal Opportunity Employer, fostering a culture of diversity, equity and inclusion, which is core to our values and important to attract and retain exceptional talent. Headquartered in Reston, Virginia, SAIC has annual revenues of approximately $7.4 billion. For more information, visit saic.com . For ongoing news, please visit our newsroom . Forward-Looking Statements Certain statements in this release contain or are based on "forward-looking” information within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as "expects,” "intends,” "plans,” "anticipates,” "believes,” "estimates,” "guidance,” and similar words or phrases. Forward-looking statements in this release may include, among others, estimates of future revenues, operating income, earnings, earnings per share, charges, total contract value, backlog, outstanding shares and cash flows, as well as statements about future dividends, share repurchases and other capital deployment plans. Such statements are not guarantees of future performance and involve risk, uncertainties and assumptions, and actual results may differ materially from the guidance and other forward-looking statements made in this release as a result of various factors. Risks, uncertainties and assumptions that could cause or contribute to these material differences include those discussed in the "Risk Factors,” "Management's Discussion and Analysis of Financial Condition and Results of Operations” and "Legal Proceedings” sections of our Annual Report on Form 10-K, as updated in any subsequent Quarterly Reports on Form 10-Q and other filings with the SEC, which may be viewed or obtained through the Investor Relations section of our website at saic.com or on the SEC's website at sec.gov . Due to such risks, uncertainties and assumptions you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. SAIC expressly disclaims any duty to update any forward-looking statement provided in this release to reflect subsequent events, actual results or changes in SAIC's expectations. SAIC also disclaims any duty to comment upon or correct information that may be contained in reports published by investment analysts or others. Media Contact: Kara Ross [email protected]The family's reunion became a celebration of hope and resilience. It served as a reminder that no matter how long the journey, the love of family can endure and conquer all obstacles. Sarah's return marked a new chapter in their lives, filled with renewed hope and the promise of a brighter future together.
TEL AVIV, Israel — Hannah Katzir, an Israeli woman who was taken hostage on Oct. 7, 2023, and freed in a brief ceasefire last year, has died. She was 78. The Hostages Families Forum, a group representing the families of people taken captive, confirmed the death Tuesday but did not disclose the cause. Her daughter, Carmit Palty Katzir, said in a statement that her mother’s “heart could not withstand the terrible suffering since Oct. 7.” Katzir’s husband, Rami, was killed during the attack by terrorists who raided their home in Kibbutz Nir Oz. Her son Elad was also kidnapped and his body was recovered in April by the Israeli military, who said he had been killed in captivity. She spent 49 days in captivity and was freed in late November 2023. Shortly after Katzir was freed, her daughter told Israeli media that she had been hospitalized with heart issues attributed to “difficult conditions and starvation” while she was held captive. In the West Bank, Bethlehem marked Christmas Eve on Tuesday in the traditional birthplace of Jesus under the shadow of war in Gaza. Latin Patriarch Pierbattista Pizzaballa, the top Roman Catholic cleric in the Holy Land, noted the shuttered shops and empty streets and expressed hope that next year would be better. “This has to be the last Christmas that is so sad,” he told hundreds of people gathered in Manger Square, where normally tens of thousands would congregate. Pizzaballa held a special pre-Christmas Mass in the Church of the Holy Family in Gaza City. The Israeli negotiating team working on a ceasefire returned from Qatar to Israel on Tuesday, the prime minister’s office said, after what it called “a significant week” of talks. After months of deadlock, the U.S., Qatar and Egypt resumed their mediation efforts in recent weeks and reported greater willingness by the warring sides to reach a deal. According to Egyptian and Hamas officials, the proposed agreement would take place in phases and include a halt in fighting, an exchange of captive Israeli hostages for Palestinian prisoners, and a surge in aid to the besieged Gaza Strip. Israel says Hamas is holding 100 hostages, over one-third of whom are believed to be dead. On Monday, Prime Minister Benjamin Netanyahu said there was “some progress” in efforts to reach a deal, but added he did not know how long it would take. Israeli soldiers took control of a hospital in isolated northern Gaza after evacuating all of the patients and most of the doctors, the Palestinian Health Ministry said Tuesday. The Israeli military confirmed its troops had entered the Indonesian Hospital in the town of Jabaliya as part of an operation searching for Hamas terrorists. The army later said its soldiers had left the hospital. The military said it had assisted with evacuating the patients and had not ordered the hospital closed. The Israeli army said Tuesday’s operation at the Indonesian Hospital came after terrorists carried out attacks from the hospital for the past month, including launching anti-tank missiles and planting explosive devices in the surrounding area. In Syria, scores of Christians protested in the capital Damascus on Tuesday, demanding greater protections for their religious minority after a Christmas tree was set on fire in the city of Hama a day earlier. Many of the insurgents who now rule Syria are jihadis, although Ahmad al-Sharaa, the leader of the main terrorist group Hayat Tahrir al-Sham, has renounced longtime ties to al-Qaida and spent years depicting himself as a champion of pluralism and tolerance. It remains unclear who set the Christmas tree on fire Monday, which was condemned by a representative of Hayat Tahrir al-Sham who visited the town and addressed the community. “This act was committed by people who are not Syrian, and they will be punished beyond your expectations,” the HTS representative said in a video widely shared on social media. “The Christmas tree will be fully restored by this evening.” On Tuesday, protesters marched through the streets of Bab Touma in Damascus, shouting slogans against foreign fighters and carrying large wooden crosses. “We demand that Syria be for all Syrians. We want a voice in the future of our country,” said Patriarch Ignatius Aphrem II of the Syriac Orthodox Church as he addressed the crowd in a church courtyard, assuring them of Christians’ rights in Syria. Meanwhile, in Syria, American journalist Austin Tice is believed to be still alive, according to the head of an international aid group. Nizar Zakka, who runs the Hostage Aid Worldwide organization, said there has never been any proof that Tice, who has been missing since 2012, is dead. Zakka told reporters in Damascus on Tuesday that Tice was alive in January and being held by the authorities of ousted Syrian President Bashar Assad. He added that President Joe Biden said in August that Tice was alive. Zakka said he believes Tice was transferred between security agencies over the past 12 years, including in an area where Iranian-backed fighters were operating. Asked if it was possible Tice had been taken out of the country, Zakka said Assad most likely kept him in Syria as a potential bargaining chip. Biden said Dec. 8 that his administration believed Tice was alive and was committed to bringing him home, although he also acknowledged that “we have no direct evidence” of his status. Back in Israel, the military said a projectile from Yemen was intercepted before crossing into Israeli territory, but it set off air raid sirens overnight in the country’s populous central area, sending residents looking for cover. Israel’s rescue service Magen David Adom said a 60-year-old woman was seriously wounded after being hurt on her way to a protected space. There was no immediate comment from Yemen’s Iranian-backed Houthi terrorists. It was the third time in a week that fire from Yemen set off sirens in Israel. On Saturday, a missile slammed into a playground in Tel Aviv, injuring 16, after Israel’s air defense system failed to intercept it.Selena Gomez, the multi-talented singer, actress, and producer, has also made a splash with her double nominations at this year's Golden Globe Awards. Recognized for her role in the critically acclaimed film "Dancing in the Moonlight" with a nomination for Best Actress in a Musical or Comedy, as well as a nod for Best Original Song for her hit single "Echoes of Love", Gomez continues to impress with her versatility and talent.
This year, e-commerce giants such as Alibaba, JD.com, Amazon, and others have all revealed their plans to capitalize on the consumer frenzy surrounding "Double 12." From limited-time flash sales to interactive games and live streaming events, these platforms are pulling out all the stops to engage shoppers and drive sales.
IRVINE, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding its DetermaCNITM assay. In a paper recently published in the journal Acta Neuropathologica Communications, DetermaCNI showed promise as a liquid biopsy method for diagnosing and profiling central nervous system tumors by measuring somatic copy number aberrations (SCNAs) in cerebrospinal fluid. For context, copy number instability (CNI) is a scientifically well-known hallmark of cancer. DetermaCNITM is a patented approach to measuring CNI for the diagnosis and monitoring of cancer. Nearly 300,000 patients in the U.S. each year face primary brain tumors or brain metastasis 1 . The current standard of care for the confirmation and classification of brain tumors often involves high-risk, highly invasive biopsy of brain tissue. Thus, a liquid biopsy method for diagnosing brain tumors could offer significant benefits over currently available methods, representing a potential $300 million U.S. market opportunity. Among the study authors were Oncocyte Chief Science Officer Ekke Schuetz and Senior R&D Director Julia Beck. "This was a proof of principle study to assess whether copy number instability could be measured in the cerebrospinal fluid of patients with brain cancer. The findings suggest that a significant number of the nearly 300,000 patients diagnosed with brain tumors every year in the U.S. could benefit from DetermaCNI,” Dr. Schuetz said. "We congratulate the research team in Frankfurt on the publication of this study in an area of high unmet need.” As noted in the paper, the gold standard for precise diagnostic classification of brain tumors requires a biopsy, with risks including limited sensitivity and failing to measure the diverse potential regions of the tumor. SCNAs were observed in the cerebrospinal fluid of ten out of the 12 patients with confirmed central nervous system cancers. SCNAs were not observed in any of the 11 patients with benign or unclear central nervous system lesions. The detection of SCNAs is highly specific for tumor-derived cell-free DNA (cfDNA). Overall, this new study demonstrates DetermaCNI's potential for providing a molecularly informed diagnosis of central nervous system cancers, mapping tumor heterogeneity, tracking tumor evolution, and surveilling tumor patients through a liquid biopsy of cerebrospinal fluid. Oncocyte believes this study validates the future clinical potential for DetermaCNI, as well as the direction of the company's research and development pipeline, which is designed to drive sustained rapid growth over the next decade. Oncocyte's mission is to democratize access to molecular diagnostic testing to improve patient outcomes. The company is investing in developing products to serve the separate verticals of organ transplant testing and oncology. Oncocyte is presently commercializing its transplant product line, which includes the VitaGraftTM and GraftAssureTM tests. It expects to commercialize its oncology assays over the next two years. _______________ 1 "Brain Metastases.” MD Anderson Cancer Center , www.mdanderson.org/cancer-types/brain-metastases.html. And "Brain Tumor Facts.” National Brain Tumor Society , 20 Feb. 2024, braintumor.org/brain-tumors/about-brain-tumors/brain-tumor-facts/. About Oncocyte Oncocyte is a diagnostics technology company. The Company's tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraftTM is a clinical blood-based dd-cfDNA solid organ transplantation monitoring test. GraftAssureTM is a research use only (RUO) blood-based solid dd-cfDNA organ transplantation monitoring test kit for decentralized use. DetermaIOTM is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNITM is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/ . For more information about our products, please visit the following web pages: VitaGraft KidneyTM - https://oncocyte.com/vitagraft-kidney/ VitaGraft Liver TM - https://oncocyte.com/vitagraft-liver/ GraftAssureTM - https://oncocyte.com/graftassure/ DetermaIOTM - https://oncocyte.com/determa-io/ DetermaCNITM - https://oncocyte.com/determa-cni/ VitaGraftTM, GraftAssureTM, DetermaIOTM, and DetermaCNITM are trademarks of Oncocyte Corporation. CONTACT: Jeff Ramson PCG Advisory (646) 863-6893 [email protected] Forward-Looking Statements Any statements that are not historical fact (including, but not limited to statements that contain words such as "will,” "believes,” "plans,” "anticipates,” "expects,” "estimates,” "may,” and similar expressions) are forward-looking statements. These statements include those pertaining to, among other things, the belief that the new study validates the future clinical potential for DetermaCNI, as well as the direction of the company's research and development pipeline, the expectation that Oncocyte will commercialize its oncology assays over the next two years, and other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Oncocyte's third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients' use of any diagnostic tests Oncocyte or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the "Risk Factors” and other cautionary statements found in Oncocyte's Securities and Exchange Commission (SEC) filings, which are available from the SEC's website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.Professional associations serve as important platforms for professionals in various fields to connect, collaborate, and advance their careers. These organizations often require members to meet certain criteria such as education, experience, and ethical standards to ensure a high level of professionalism within the industry. However, a concerning trend has been emerging where some professional associations seem to prioritize membership fees over the quality and standards of their members.
Treasury Secretary Janet Yellen said her agency will need to start taking "extraordinary measures," or special accounting maneuvers intended to prevent the nation from hitting the debt ceiling, as early as January 14, in a letter sent to congressional leaders Friday afternoon. "Treasury expects to hit the statutory debt ceiling between January 14 and January 23," Yellen wrote in a letter addressed to House and Senate leadership, at which point extraordinary measures would be used to prevent the government from breaching the nation's debt ceiling — which has been suspended until Jan. 1, 2025. The department has in the past deployed what are known as "extraordinary measures" or accounting maneuvers to keep the government operating. But once those measures run out the government risks defaulting on its debt unless lawmakers and the president agree to lift the limit on the U.S. government's ability to borrow. "I respectfully urge Congress to act to protect the full faith and credit of the United States," she said. The news comes after President Joe Biden signed a bill into law last week that averted a government shutdown but did not include President-elect Donald Trump's core debt demand to raise or suspend the nation's debt limit. The bill was approved by Congress only after fierce internal debate among Republicans over how to handle Trump's demand. "Anything else is a betrayal of our country," Trump said in a statement. After a protracted debate in the summer of 2023 over how to fund the government, policymakers crafted the Fiscal Responsibility Act, which included suspending the nation's $31.4 trillion borrowing authority until Jan. 1, 2025. Notably however, Yellen said, on Jan. 2 the debt is projected to temporarily decrease due to a scheduled redemption of nonmarketable securities held by a federal trust fund associated with Medicare payments. As a result, "Treasury does not expect that it will be necessary to start taking extraordinary measures on January 2 to prevent the United States from defaulting on its obligations," she said. The federal debt currently stands at roughly $36 trillion — which ballooned across both Republican and Democratic administrations. And the spike in inflation after the coronavirus pandemic pushed up government borrowing costs such that debt service next year will exceed spending on national security. Republicans, who will have full control of the White House, House and Senate in the new year, have big plans to extend Trump's 2017 tax cuts and other priorities but debate over how to pay for them.
Despite the current downward trend, some experts believe that gold prices may rebound in the near future. Factors such as increased demand for safe-haven assets during times of economic volatility and geopolitical uncertainty could drive prices higher. Additionally, the ongoing impact of the COVID-19 pandemic on global economies may also play a role in shaping the future direction of gold prices.
Five Below, Inc. Names Winnie Park Chief Executive OfficerGlobal Launch of JETOUR T2 i-DM: Reshaping the Hybrid SUV Market
The stock market in both Shanghai and Shenzhen witnessed a fiery scene as a total of 100 listed stocks hit the daily limit-up on the same trading day. This extraordinary event has once again brought the spotlight onto the frenzied and volatile nature of the equity market.
